The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second-line chemotherapy in patients with biliary tract cancer.
G. Brandi
No relevant relationships to disclose
S. Di Girolamo
No relevant relationships to disclose
F. de Rosa
No relevant relationships to disclose
J. Corbelli
No relevant relationships to disclose
V. Agostini
No relevant relationships to disclose
I. Garajova
No relevant relationships to disclose
C. Longobardi
No relevant relationships to disclose
M. Paragona
No relevant relationships to disclose
G. Ercolani
No relevant relationships to disclose
A. D. Pinna
No relevant relationships to disclose
G. Biasco
No relevant relationships to disclose